<code id='008A105C96'></code><style id='008A105C96'></style>
    • <acronym id='008A105C96'></acronym>
      <center id='008A105C96'><center id='008A105C96'><tfoot id='008A105C96'></tfoot></center><abbr id='008A105C96'><dir id='008A105C96'><tfoot id='008A105C96'></tfoot><noframes id='008A105C96'>

    • <optgroup id='008A105C96'><strike id='008A105C96'><sup id='008A105C96'></sup></strike><code id='008A105C96'></code></optgroup>
        1. <b id='008A105C96'><label id='008A105C96'><select id='008A105C96'><dt id='008A105C96'><span id='008A105C96'></span></dt></select></label></b><u id='008A105C96'></u>
          <i id='008A105C96'><strike id='008A105C96'><tt id='008A105C96'><pre id='008A105C96'></pre></tt></strike></i>

          knowledge

          knowledge

          author:Wikipedia    Page View:9359
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Mass General, Mayo Clinic look to monetize custom
          Mass General, Mayo Clinic look to monetize custom

          AdobeHospitalsaren’tusuallyinthebusinessofsellingtechnologytools.Butthat’schangingthankstoacollision

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

          CourtesySanofiLONDON—Inabidtoexpanditspipelineofinflammation-targetingdrugs,SanofisaidTuesdayitwasac